AR and breast cancer: Similar to breast cancer where they inhibit E2 signaling, HDAC inhibitors or HDAC1/3 knockdown suppresses AR signaling in prostate cancer cells by preventing recruitment of AR coactivators, SRC1 and p300 to AR target genes (104).